AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00270647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-carotene
Description: 50 mg Lurotin or placebo on alternate days (provided by BASF)
Study NCT02624375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine Live
Study NCT04897685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flow with Nature
Description: Nature-based intervention was facilitated by a health care professional and included 12 x 90 mins sessions within 12 weeks.
Study NCT01538992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard steerable Marinr RF ablation Catheter (5F or 7F)
Description: Intervention: Device: Standard steerable Mariner Radiofrequency ablation Catheter (5F or 7F)
Study NCT01220856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: Reparixin + immunosuppression
Study NCT03726983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Pregnant women who agree to take part will be assigned to a group: experimental group and control group. The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
Study NCT04306549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bulk-Fill and Microhybrid Composite Resins
Description: Clinical Comparison of Composite Restorations (Two Bulk-Fill and one Microhybrid Composite Resin) to the USPHS Criterias
Study NCT03628690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BandGrip
Description: Topical skin closure device
Study NCT03628690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Wound closure
Study NCT04641416 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Routinely performed echo, ECG and hemodynamic monitoring
Description: The pump data of patients on the ICU or normal ward are stored in a continuous data acquisition system (CDAS) on a notebook which is operated in battery operation, and analyzed afterwards with a mat-lab based software. For outpatients a mobile data-recorder will allow a continuous data acquisition for a period up to 2 months on a SD card. During this non-invasive pump data monitoring, routinely available hemodynamic monitoring, ECG and echo data will be collected.
Study NCT02176837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
Study NCT04360434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI006
Description: NI006 will be administered intravenously
Study NCT04360434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously
Study NCT00618917 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Manganese Superoxide Dismutase Plasmid Liposome
Description: 15 ml of liquid that contains either 0.3 mg, 3.0 mg or 30.0 mg (depending on which cohort is open when the subject is entered) of MnSOD PL This will be given on Day 1 and 3 of each week of the experimental treatment for a total of 14 doses.
Study NCT00618917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Chemotherapy to stop the growth of tumor cells.
Study NCT00618917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Chemotherapy to stop the growth of tumor cells. This drug kills tumor cells by inducing multipolar divisions. Cells entering mitosis in the presence of concentrations of paclitaxel equivalent to those in human breast tumors form abnormal spindles that contain additional spindle poles.
Study NCT00618917 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
Study NCT04452409 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser
Description: The laser therapy device (660 nm) consisted of abdominal straps containing 4 LED clusters, having 72 LEDs each, applied in the study group paticipants around the patients abdomen and waist after cleaning the target area and wearing safety goggles20, for 30 min., 2 times per week over 12 weeks
Study NCT04452409 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mediterranean diet
Description: recommend healthy diet component evaluated periodically by 24 hour recall
Study NCT04452409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: recommend healthy diet component evaluated periodically by 24 hour recall
Study NCT01458964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: 100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
Study NCT01218425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate 40 mg
Description: Oral dose 40 mg
Study NCT01218425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 125 mg
Description: oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule
Study NCT01218425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidon 10 mg
Description: Domperidon 10 mg
Study NCT03161223 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Durvalumab
Description: Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).~Starting dose: 1500 mg
Study NCT03161223 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pralatrexate
Description: Pralatrexate is an antimetabolite drug. Pralatrexate alone is FDA-approved for the treatment of PTCL. Given intravenously (through the vein).~Starting dose: 25 mg/m2
Study NCT03161223 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Romidepsin
Description: Romidepsin is another type of chemotherapy known as histone deacetylase (HDAC) inhibitors. Romidepsin has not been approved for use in lymphoma other than Cutaneous T cell lymphoma (CTCL) by the FDA. Given intravenously (through the vein).~Starting dose: 12 mg/m2
Study NCT03161223 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-Azacitidine
Description: Oral 5-azacitidine is used for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Azacitidine prevents the body from making DNA and RNA that cells need to grow. This stops the growth of cancer cells and causes them to die. Given by mouth (orally).~Starting dose: 300 mg daily
Study NCT00528710 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: SAM-e (S-Adenosyl-L-Methionine)
Description: One 400 mg tablet daily in the morning.
Study NCT04498988 — intervention group
Intervention type: OTHER
Intervention: Observational study without interventions
Study NCT04320953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-contact MCE system
Description: After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination.
Study NCT02277067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
Study NCT02277067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
Study NCT01717391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorothymidine F 18
Description: A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
Study NCT00695825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low GI+high GI
Description: Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
Study NCT00695825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High GI+low GI
Description: Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
Study NCT00658840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda®)
Description: Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
Study NCT00658840 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Localization, simulation and immobilization
Description: Radiation dose and planning~1. Total dose 55.8Gy, 28 fractions, 6-7 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to emcompass GTV with a margin of 1-1.5cm.~2. Dose prescription : 90% isodose volume of prescribed dose encompassed PTV~3. The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the liver, duodenum, stomach, the kidneys, spinal cord, etc., was calculated.
Study NCT02037256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT02037256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT02037256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous hematopoietic stem cell transplantation
Study NCT02945254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIghtingale (R) device for filtered white noise (Cambridge Sound Management, Waltham, MA)
Study NCT03396536 — intervention group
Intervention type: OTHER
Intervention: Evaluation of KM
Description: KM will be evaluated. The alveolar mucosa will be stained with Lugol's solution, by means of a cotton swab. A cotton roll will be soaked in the solution and gently applied on the mucosa around the implant. Since Lugol's solution is selective to the glycogen present in AM, the muco-gingival junction as the borderline between the blue-stained alveolar mucosa and KM can be easily identified.~A manual periodontal probe with 1 mm markings will measure the distance from the peri-implant margin and the muco-gingival junction.~Mucosal thickness (MT) will be measured after topical application of the anesthetics. MT will be evaluated inserting a 27G needle with a rubber stop 1 mm below the peri-implant mucosal margin at the mid-buccal aspect, until the abutment is engaged. The needle will be removed and the distance between the rubber stop and the point of the needle will be measured with a manual periodontal probe.
Study NCT02847026 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 14 and 22 weeks of age, Rotarix
Description: Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
Study NCT02847026 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 14 and 22 weeks of age, RotaTeq
Description: Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
Study NCT02847026 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 14 and fIPV at 22 weeks, Rotarix
Description: Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
Study NCT02847026 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 14 and fIPV at 22 weeks, RotaTeq
Description: Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
Study NCT01341639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq
Description: RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) 2 mL oral dose at 2, 3, and 4 months of age
Study NCT01341639 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age
Study NCT01341639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age
Study NCT01341639 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad™
Description: ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age
Study NCT01341639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad™
Description: ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age
Study NCT01781039 — intervention group
Intervention type: DEVICE
Intervention: Hearing Aid fitting
Description: Subjects with hfPTAs ranging from 0-55 dB HL will be recruitedwith 100 persons self-reporting difficulty HIN (> 50% of the time), and 100 persons reporting little difficulty HIN (\< 50% of the time) will be randomly assigned to one of five groups (n = 200) based on enabled HA features using an online random assignment tool. Unaided HIQ and HIN assessments will be conducted in the sound field, and baseline DPOAE and CAP assessments will be measured. Subjects will be fit with binaural premium level receiver-in-the canal HAs (Phonak B90 or equivalent model at the start of the study) with 56 dB SPL gain receivers, using closed domes, and programmed to NAL-NL2 target gain, and randomly assigned to the groups.
Study NCT00795561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Day care
Description: Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
Study NCT00795561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient
Description: Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
Study NCT00406757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine injection 400mg/m2
Description: Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.~Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5.
Study NCT00406757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine injection 650mg/m2
Description: Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
Study NCT00406757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine injection 1000mg/m2
Description: Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
Study NCT00406757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine injection 1500mg/m2
Description: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
Study NCT01058161 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: high-field MRI (3 Teslas)
Description: high-field MRI (3 Teslas)
Study NCT01853306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: veliparib
Study NCT04125628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise with cooling
Description: The exercise training session involved head cooling and neck wraps. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the condition each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed
Study NCT04125628 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise without cooling
Description: The exercise session performed without cooling. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
Study NCT01336894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT01336894 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: iodine I 125
Description: Undergo seed implant radiotherapy
Study NCT01336894 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo radiotherapy
Study NCT01352702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Patients assigned to this group will receive Dabigatran
Study NCT01352702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: Patients assigned to this group will receive Phenprocoumon
Study NCT01273532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER 100-mg TRF
Description: 100mg TRF single oral dose
Study NCT01273532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER 50-mg TRF
Description: 100 mg TRF single oral dose
Study NCT05039034 — intervention group
Intervention type: OTHER
Intervention: Advice according to primary prevention guidelines on stroke of China
Study NCT02312674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement
Description: Beginning with the start of palliative therapy, depending on the nutritional status, one, two, or three cans per day are ingested during a period of three months.
Study NCT02171182 — intervention group
Intervention type: DRUG
Intervention: Qutenza
Description: capsaicin patch
Study NCT00566358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal exclusion surgery
Description: Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create an excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
Study NCT02513992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-arterial injection of tracer
Description: intra-arterial ictal injection of perfusion tracer
Study NCT02513992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99m-Technetium Ethyl Cysteinate Dimer
Description: administration of perfusion tracer 99m Tc-ECD during epileptic seizure
Study NCT02513992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-arterial catheter
Description: placement of intra-arterial catheter via femoral artery
Study NCT02513992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure injector
Description: the injection of the perfusion tracer will be delivered with a pressure injector
Study NCT03115008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-based terminal feedback
Description: Terminal feedback is given after skill performance using video-based coaching coupled with a validated polypectomy assessment tool
Study NCT04478227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Study NCT01133860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.